Fi3 FINANCIAL ADVISORS LLC Buys Shares of 10,280 Bristol Myers Squibb Company $BMY

Fi3 FINANCIAL ADVISORS LLC bought a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 10,280 shares of the biopharmaceutical company’s stock, valued at approximately $554,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. waypoint wealth counsel purchased a new position in shares of Bristol Myers Squibb in the fourth quarter valued at $1,194,000. Phoenix Financial Ltd. increased its position in shares of Bristol Myers Squibb by 110.1% in the third quarter. Phoenix Financial Ltd. now owns 106,154 shares of the biopharmaceutical company’s stock valued at $4,789,000 after buying an additional 55,624 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Bristol Myers Squibb by 4.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,211,845 shares of the biopharmaceutical company’s stock valued at $99,754,000 after buying an additional 93,528 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of Bristol Myers Squibb by 6.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 531,538 shares of the biopharmaceutical company’s stock valued at $23,972,000 after buying an additional 32,005 shares in the last quarter. Finally, M&G PLC increased its position in shares of Bristol Myers Squibb by 1.4% in the third quarter. M&G PLC now owns 6,885,188 shares of the biopharmaceutical company’s stock valued at $309,833,000 after buying an additional 97,063 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 0.2%

BMY opened at $58.45 on Thursday. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The stock has a market capitalization of $119.37 billion, a price-to-earnings ratio of 16.42, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The business has a 50-day moving average of $58.48 and a two-hundred day moving average of $55.73. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.42 by $0.16. The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm’s revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts expect that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were issued a $0.63 dividend. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 annualized dividend and a yield of 4.3%. Bristol Myers Squibb’s payout ratio is 70.79%.

Analysts Set New Price Targets

BMY has been the subject of a number of research analyst reports. UBS Group restated a “buy” rating and issued a $70.00 price target on shares of Bristol Myers Squibb in a research report on Friday, March 6th. Wells Fargo & Company restated an “outperform” rating and issued a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Guggenheim restated a “buy” rating and issued a $72.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Piper Sandler restated an “overweight” rating and issued a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Finally, Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Sunday, April 19th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of “Hold” and a consensus target price of $61.31.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a strategic agreement with Anthropic to make Claude Enterprise available across its global operations, including more than 30,000 employees, with use cases spanning research, drug development, manufacturing, and commercial functions. The deal may help accelerate discovery and lower operating friction. Article Title
• Positive Sentiment: Multiple reports confirmed Bristol Myers Squibb is deploying Anthropic’s Claude AI tools to speed up drug discovery and broaden AI adoption across the company, reinforcing the market’s view that BMY is investing in productivity-enhancing technology. Article Title
• Positive Sentiment: Tempus AI also announced an expanded collaboration with Bristol Myers Squibb to improve clinical trial design and increase the probability of success across five development programs, which supports the company’s pipeline execution story. Article Title
• Neutral Sentiment: Coverage pieces from Seeking Alpha, Yahoo Finance, and Zacks indicate BMY is a closely watched stock right now, but these items appear more descriptive than fundamentally new. Article Title
• Neutral Sentiment: Recent commentary also continues to focus on pipeline hopes, patent risks, and valuation moves, which keep investor attention on long-term execution rather than near-term financial results. Article Title

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the sale, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.05% of the stock is owned by company insiders.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.